Abstract
Cryptococcusalbidus and Cryptococcuslaurentii are uncommon species of this genus that in recent decades have increasingly caused opportunistic infections in humans, mainly in immunocompromised patients; the best therapy for such infection being unknown. Using a murine model of systemic infection by these fungi, we have evaluated the efficacy of amphotericin B (AMB) at 0.8mg/kg, administered intravenously, fluconazole (FLC) or voriconazole (VRC), both administered orally, at 25mg/kg and the combination of AMB plus VRC against three C.albidus and two C.laurentii strains. All the treatments significantly reduced the fungal burden in all the organs studied. The combination showed a synergistic effect in the reduction in fungal load, working better than both monotherapies. The histopathological study confirmed the efficacy of the treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have